Shots:
- Grünenthal has entered into an agreement with Bayer to acquire Stivarga for ~€375M (~$430.67M), subject to customary closing conditions incl. regulatory approval, with the transaction expected to close by the end of 2026 or early 2027
- Stivarga (regorafenib) is an oral multikinase inhibitor indicated for metastatic colorectal cancer, hepatocellular carcinoma, & gastrointestinal stromal tumours in pts previously treated with, or unable to receive, other available therapies
- Stivarga is expected to lose exclusivity in 2029 in the EU and in 2030 in the US
Ref: PRnewswire | Image: Grünenthal & Bayer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
